[
  {
    "ts": null,
    "headline": "Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application",
    "summary": "TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for EYLEA HD® (aflibercept) Injection 8 mg across all approved indications. The CRL did not identify any issues with the safety or efficacy of EYLEA HD in its",
    "url": "https://finnhub.io/api/news?id=c98a9ee76e377f5fc66def388564365d2a4b0b93c1198c9049b6c2e28d38f16b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745002800,
      "headline": "Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application",
      "id": 133969992,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for EYLEA HD® (aflibercept) Injection 8 mg across all approved indications. The CRL did not identify any issues with the safety or efficacy of EYLEA HD in its",
      "url": "https://finnhub.io/api/news?id=c98a9ee76e377f5fc66def388564365d2a4b0b93c1198c9049b6c2e28d38f16b"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron to Reassess Strategy for Retinal Condition Treatment After FDA Rejects Dosing Plan",
    "summary": "By Connor Hart Regeneron Pharmaceuticals said it is working to determine a path forward for its treatment of several retinal conditions after the Food and Drug Administration said it didn't agree...",
    "url": "https://finnhub.io/api/news?id=f4236cbc24d2149a5dbc54b9e6da4fca4c5b254a170b86f3a920d5e7768fa573",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744991587,
      "headline": "Regeneron to Reassess Strategy for Retinal Condition Treatment After FDA Rejects Dosing Plan",
      "id": 133966707,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "By Connor Hart Regeneron Pharmaceuticals said it is working to determine a path forward for its treatment of several retinal conditions after the Food and Drug Administration said it didn't agree...",
      "url": "https://finnhub.io/api/news?id=f4236cbc24d2149a5dbc54b9e6da4fca4c5b254a170b86f3a920d5e7768fa573"
    }
  },
  {
    "ts": null,
    "headline": "Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)",
    "summary": "Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced",
    "url": "https://finnhub.io/api/news?id=cc977429649f012c9693423935b8f189f80e849eb9b116a028d46eb7d37d8c06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744989300,
      "headline": "Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)",
      "id": 133969993,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced",
      "url": "https://finnhub.io/api/news?id=cc977429649f012c9693423935b8f189f80e849eb9b116a028d46eb7d37d8c06"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron, Sanofi Get FDA Approval For Dupixent in Skin Disease CSU",
    "summary": "Regeneron, Sanofi Get FDA Approval For Dupixent in Skin Disease CSU",
    "url": "https://finnhub.io/api/news?id=b6b94f07833440ce17d60f915ea784f66cf53ecb155f1024bd98286998f29d9e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744976040,
      "headline": "Regeneron, Sanofi Get FDA Approval For Dupixent in Skin Disease CSU",
      "id": 134077226,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron, Sanofi Get FDA Approval For Dupixent in Skin Disease CSU",
      "url": "https://finnhub.io/api/news?id=b6b94f07833440ce17d60f915ea784f66cf53ecb155f1024bd98286998f29d9e"
    }
  }
]